UNCY

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming November 2, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON UNICYCIVE THERAPEUTICS, INC. (UNCY), CLICK HERE TO.

New York, New York--(Newsfile Corp. - September 7, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Unicycive securities between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period").

LOS ANGELES--(BUSINESS WIRE)---- $UNCY--Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – UNCY.

New York, New York--(Newsfile Corp. - September 6, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Unicycive securities between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period").

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options

ATLANTA, Sept. 04, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Unicycive Therapeutics, Inc. (“Unicycive”) (NASDAQ: UNCY). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts, including allegations that: (1) Unicycive had not inspected its third-party manufacturing vendor's facility or otherwise audited the facility's compliance with current good manufacturing practices; (2) as a result, Unicycive lacked a reasonable basis to believe that the vendor had resolved the FDA's cited deficiencies; (3) there was an undisclosed risk that the FDA would require additional information about the vendor's facility's manufacturing practices; (4) as a result of the foregoing, the regulatory approval of oxylanthanum carbonate was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants' positive statements about Unicycive's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) common stock between December 29, 2025 and June 29, 2026, inclusive (the “Class Period”). Unicycive Therapeutics, Inc. investors have until November 2, 2026 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN UNICYCIVE THERAPEUTICS, INC. (UNCY).

SAN DIEGO--(BUSINESS WIRE)---- $UNCY #UNCY--Robbins LLP is Investigating Allegations that Unicycive Therapeutics, Inc. Failed to Clean Up Deficiencies at its Vendor's Manufacturing Facility.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP (“GPWR”), announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Patel v. Unicycive Therapeutics, Inc. et al., Case No. 25-cv-09559, on behalf of persons and entities that purchased or otherwise acquired Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026, inclusive (th.

LOS ALTOS, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 11 a.m. ET.